Abstract
Introduction
Magnetic resonance imaging (MRI) has become an important diagnostic modality for hepatic tumors. With advances in hardware and three-dimensional reconstruction techniques, MRIs can shorten the acquisition time and provide better imaging quality.
1e3 Contrast-enhanced images are important for diagnosing hypervascular tumors, such as hepatocellular carcinomas (HCCs). 4e6 The paramagnetic object, gadolinium (Gd), combined with the chelating agent, diethylenetriamine pentaacetic acid (DTPA), has been used as an MRI contrast agent for a long time. When injected intravenously, it distributes throughout the extracellular fluid, producing contrast enhancement in the T1-weighted image, and provides dynamic-enhanced information. GdeDTPA is then completely excreted by the urinary system.
There are several hepatocyte-specific contrast agents, such as superparamagnetic iron oxide nanoparticles, gadobenate dimeglumine, and gadoliniumeethoxybenzylediethylenetriamine pentaacetic acid (GdeEOBeDTPA). 7e9 GdeEOBeDTPA is a newly developed hepatocyte-specific contrast agent with combined perfusion and hepatocyte-selective properties. With the lipophilic ethobenzyl group, it can enter hepatocytes via an organic anion-transport system, and is excreted into the biliary system (43.1e53.2%) and urinary system (41.6e51.2%) separately. 8e11 The information obtained from contrast-enhanced MRIs provides different enhancement features for hepatic tumors and helps in the differential diagnosis. However, contrast uptake of the background liver parenchyma affects the appearance of hepatic tumors. The hepatic and renal functions may lead to different contrast uptakes of the liver parenchyma, especially for hepatocyte-specific contrast agents.
12e14 Most patients undergo GdeEOBeDTPA-enhanced MRIs for the diagnosis of hepatic tumors, especially HCCs. Most of the HCCs develop in abnormal livers, such as those with diffuse liver disease or liver cirrhosis. The underlying liver disease, liver function, and renal function may play important roles in the diagnostic ability of contrast-enhanced MRIs. The different excretion pathways between GdeEOBeDTPA and GdeDTPA may also affect the enhancing pattern. The purpose of this study was to compare the differences in the enhancement of the liver and kidney between GdeDTPA and GdeEOBeDTPA for patients with liver cirrhosis.
Methods

Subjects
This study was approved by the Institutional Review Board of our hospital. We retrospectively included consecutive patients with hepatic tumors and liver cirrhosis. The inclusion criteria for patients were (1) having liver cirrhosis and the presence of hepatic tumors; (2) having no previously existing malignancy or treatment history; and (3) having undergone both GdeDTPA-and GdeEOBeDTPA-enhanced MRIs within the past 3 months. A total of 49 patients (32 men and 17 women; mean age: 59 years old, range: 28e80 years old) enrolled in this study from December 2009 to March 2012. Among them, all patients had liver cirrhosis (39 hepatitis B virus-related cirrhosis, 5 hepatitis C virus-related cirrhosis, 3 alcoholic cirrhosis, 1 both hepatitis B þ C virus related, and 1 hepatitis B virus-related and alcoholic cirrhosis; 38 ChildePugh class A disease, 9 ChildePugh class B disease, and 2 ChildePugh class C disease). Furthermore, we divided the patients into two groups (normal/abnormal) according to their serum-bilirubin levels and aspartate aminotransferase/alanine transaminase (AST/ALT), respectively, to assess the different enhancement effects in the serum bilirubin, AST/ALT, and ChildePugh classifications.
Imaging methods
The MRIs were performed with a Achieva 1. ; FOV: 38e40 cm) and fat sat T1WI were performed during one breath hold. Automatic shimming was used for fat-suppression imaging to maximize the magnetic-field homogeneity. Flow compensation was also used.
All patients received 0.1 mmol/kg GdeDTPA (Magnevist; Bayer Schering Pharma AG, Berlin, Germany) for the GdeDTPA-enhanced MRI examination. All of them received 0.025 mmol/kg GdeEOBeDTPA (Primovist; Bayer Schering Pharma AG) for the GdeEOBeDTPA-enhanced MRI. The contrast agent was injected as a bolus at a speed of nearly 2 mL/second through peripheral veins. Dynamic threedimensional T1-weighted fast-field-echo sequence (TR/TE: 5e10/3.3 milliseconds; slice thickness: 5 mm; matrix: 192 Â 256; NEX: 1; flip angle: 10 ; FOV: 38e40 cm) was carried out before, in 8e20 seconds [arterial phase (AP)], 50e55 seconds [portal venous phase (PP)], and 85e90 seconds [venous phase (VP)] following the contrast-agent injection. In addition, delayed-phase (DP) images (180 seconds after the injection of the contrast agent) were acquired when GdeDTPA was used, and hepatocyte-phase (HP) images (20 minutes after the injection of the contrast agent) were acquired when the GdeEOBeDTPA was used.
Imaging analysis
Two experienced radiologists with more than 15 years' experience in abdominal MRI reviewed all the GdeDTPA-and GdeEOBeDTPA-enhanced MRI images. Any difference of opinion between the two radiologists was resolved by a third radiologist who was also blinded to the clinical information.
The imaging analysis was performed at a dual-screen diagnostic workstation (GE Healthcare, Milwaukee, WI, USA). The signal intensities (SIs) of the liver and kidney were measured by the radiologists using regions of interest (ROI). Each ROI was a circle or oval. For measurements of the liver parenchyma, the ROI with an area of at least 200 mm 2 was placed at a location in the right posterior segment and devoid of large vessels. For SI measurements of the kidney, the image was magnified up to two times because of the organ's small size. The ROI with an area of at least 10 mm 2 was located in the bilateral renal cortex and medulla. The SIs were measured twice and the measurements averaged. The enhancement ratio (ER) of the liver and kidney at all phases was calculated from the SI measurements before (SI pre) and after (SI post) administration of GdeDTPA or GdeEOBeDTPA. The ratio is (SI post e SI pre)/SI pre. The differences in the ERs between the two contrast agents were evaluated.
Statistical analysis
The data were presented as mean ± standard deviation. The different ERs from the GdeDTPA and GdeEOBeDTPA for the liver, renal cortex, and renal medulla at all phases were compared by linear mixed models. The linear mixed model was also used to analyze the differences in the ERs for the GdeDTPA and GdeEOBeDTPA in the different serum bilirubin, AST/ALT, and ChildePugh classifications. Interobserver differences between the two observers were evaluated with the kappa test and interpreted as moderate for 0.4 < k 0.60, good for 0.6 < k 0.80, and excellent for k > 0.80. Statistical analyses were performed using SAS (version 9.2; SAS Inc., Cary, NC, USA). A p value of <0.05 was considered statistically significant.
Results
The interobserver agreement by the kappa analysis showed excellent agreement (k ¼ 0.91). The ER results of the liver and kidney at dynamic study, DP, and HP obtained with GdeDTPA and GdeEOBeDTPA are summarized in Table 1 . Comparing the enhancement effect of the liver between the GdeDTPA and GdeEOBeDTPA, the ER of the liver in VP with GdeEOBeDTPA (0.47 ± 0.46) was significantly higher than with GdeDTPA (0.32 ± 0.44) ( p ¼ 0.01). The ER in HP with GdeEOBeDTPA (0.49 ± 0.53) was significantly higher than in DP with GdeDTPA (0.33 ± 0.45) ( p ¼ 0.01) (Figs. 1  and 2 ). Over all the phases, the average ER of the liver with GdeEOBeDTPA (0.40 ± 0.42) was significantly higher than with GdeDTPA (0.28 ± 0.35) ( p ¼ 0.004).
The ERs of the renal cortex in PP and VP with GdeEOBeDTPA were significantly higher than with GdeDTPA ( p ¼ 0.03; p ¼ 0.01). The ER of the renal medulla in VP with GdeDTPA (1.54 ± 1.03) was significantly higher than with GdeEOBeDTPA (1.14 ± 0.62) ( p ¼ 0.001). However, the average ER of the whole kidney (the average ER of the renal cortex and medulla) in DP with GdeDTPA was significantly higher than in HP with GdeEOBeDTPA ( p < 0.0001) (Figs. 1 and 3) . Over all the phases, the ER of the whole kidney with GdeDTPA (1.16 ± 0.86) was significantly higher than with GdeEOBeDTPA (0.99 ± 0.67) ( p ¼ 0.01).
The differences between the ERs of the liver and kidney in the dynamic phases and HP obtained from GdeDTPA and GdeEOBeDTPA for different serum bilirubin, AST/ALT, and ChildePugh classifications are summarized in Tables 2 and 3 . In the GdeDTPA-enhanced MRI, the ERs of the liver and kidney showed no significant difference between the patients with normal and abnormal liver functions (such as serum bilirubin, AST, and ALT). There were also no significant differences between the patients using the ChildePugh classification. However, the ERs of the liver in the HP using GdeEOBeDTPA for patients with normal serum bilirubin were significantly higher than for patients with abnormal serum bilirubin ( p ¼ 0.047). In the different AST/ALT and ChildePugh classifications, the ERs of the liver and kidney using GdeEOBeDTPA showed no significant differences.
Discussion
In contrast-enhanced imaging studies, the enhancement of the liver parenchyma influences the detection of hepatic lesions. To diagnose nodular lesions in patients with liver cirrhosis is difficult in daily practice due to the heterogeneous enhancement of the background liver. GdeEOBeDTPA is a hepatocyte-specific MRI contrast agent, and is excreted through both the biliary and urinary systems. It is different from the traditional extracellular MRI contrast agent, GdeDTPA, which is excreted exclusively through the urinary system. Many studies have discussed the enhancement patterns of different lesions with GdeEOBeDTPA, 7 ,15 but few have discussed the enhancement of the liver and kidney parenchyma. 16 In the present study, we compared the enhancement effect of the liver and renal parenchyma between these two contrast agents for patients with liver cirrhosis. Our results showed that the ER of the liver with GdeEOBeDTPA was significantly higher than with GdeDTPA in the VP ( p ¼ 0.01) and in the HP/DP ( p ¼ 0.01). The ER of the kidney in the DP with GdeDTPA was significantly higher than in the HP with GdeEOBeDTPA ( p < 0.001). The different enhancement may be due to their different excretion pathways. 10 Tamada et al 17 compared the AP, VP, and DP (about 180 seconds after the injection of the contrast agent) between these two contrast agents. Their results showed that the enhancements of the liver parenchyma and whole kidney in the AP with GdeEOBeDTPA were lower than those with GdeDTPA. Conversely, the enhancement of the liver parenchyma during the DP with GdeEOBeDTPA was higher. 17 Our results were similar in the PP and VP, but there was no significant difference in the AP. According to the American Association for the The enhancement ratios (ERs) of the kidney with GdeDTPA maintained enhancement and reached peak enhancement in DP. However, the ERs of the kidney with GdeEOBeDTPA reached peak enhancement in PP, and then decreased. The ERs of the kidney in DP with GdeDTPA were significantly higher than in hepatocyte phase with GdeEOBeDTPA.
Study of Liver Diseases, the typical enhancing pattern of HCC is hypervascular in the AP and washout in the late phase or DP. 18 Lesion detection is influenced by contrast enhancement of the lesions themselves and the background tissue. According to our results, there may be no difference in the detection of arterial hypervascularity in the liver using both contrast agents. However, the higher enhancement of the liver parenchyma in the late phase and DP in the GdeEOBeDTPAenhanced MRI may increase the liver-to-lesion contrast and help in detecting the washout phenomenon of HCC. In the HP of the GdeEOBeDTPA-enhanced MRI, our results were similar to those of previous studies. The uptake of the liver parenchyma in the HP increased the liver-to-lesion contrast and increased the detection of liver lesions. 16,19e22 We suggest that GdeEOBeDTPA could provide better diagnostic information than GdeDTPA in the VP, DP, and HP. Some studies have indicated that insufficient liver enhancement is related to the patient's liver dysfunction. 23, 24 Some studies have also evaluated the impact of liverfunction factors for liver parenchymal enhancement with GdeEOBeDTPA with different conclusions. 12, 13, 25, 26 In this study, we assessed the ERs in the liver in the dynamic study, DP, and HP obtained from GdeDTPA and GdeEOBeDTPA based on the serum-bilirubin level, AST/ALT, and ChildePugh classifications. There was no difference between the normal and abnormal AST/ALT. However, a higher ER was found in patients with normal serum-bilirubin level significantly. GdeEOBeDTPA is a hepatocyte-specific MRI contrast agent approximately 50% of which is excreted through the biliary system. 10 Previous literature had reported that serum-bilirubin levels are related to the function of excretion; they may affect the liver enhancement in GdeEOBeDTPA-enhanced MRIs. 25, 26 Our study used a serum-bilirubin level of 1.2 mg/dL to divide the patients into normal and abnormal groups, while Tajima et al 13 used 1.3 mg/dL. The liver enhancements were lower in patients with abnormal bilirubin levels than in those with normal bilirubin levels in both our study and in previous ones; the abnormal serum-bilirubin levels may affect the lesiondetection ability of GdeEOBeDTPA-enhanced MRIs. Table 2 Enhancement ratios in the liver and kidney in the dynamic study, delayed, and hepatocyte phases obtained with gadoliniumediethylenetriamine pentaacetic acid and gadoliniumeethoxybenzylediethylenetriamine pentaacetic acid according to ChildePugh classification.
Contrast
Organ Phase ChildePugh classification Table 3 Enhancement ratios in the liver and kidney in the dynamic study, delayed, and hepatocyte phases obtained with gadoliniumediethylenetriamine pentaacetic acid and gadoliniumeethoxybenzylediethylenetriamine pentaacetic acid according to the total bilirubin and aspartate aminotransferase/alanine transaminase. Motosugi et al 12 reported that the ChildePugh classification, which combines five factors (serum albumin, bilirubin levels, prothrombin activity, ascites levels, and the presence or absence of hepatic encephalopathy), was able to indicate liver function more accurately and significantly correlated with liver enhancement. Kim et al 26 indicated that the liver parenchymal enhancement of GdeEOBeDTPA was affected by the ChildePugh classification. Chou et al 19 showed that the enhancement of the liver for patients with ChildePugh class C was lower than for those of class A and class B, but no significant difference was found. In our study, there were no significant differences between the ChildePugh classes, but the number of patients with ChildePugh classes B and C was relatively small as compared to class A. Therefore, we suggest that future studies should include more patients with classes B and C for further evaluation.
The ER data of renal cortex and medulla were different in every phase for both contrast agents. However, the significant differences were noted mainly in VP and DP/HP. Overall, the ERs of the kidney with GdeDTPA were significantly higher than with GdeEOBeDTPA at DP/HP, which may be due to the excretion of GdeDTPA exclusively into the urinary system. The serum bilirubin, AST/ALT, and ChildePugh classifications did not affect the enhancement of the kidney with either GdeDTPA or GdeEOBeDTPA.
This study had several limitations. First, the number of ChildePugh class B and class C patients was relatively small in the present study; however, the proportions of patients based on the ChildePugh score represent a similar distribution for the general population. Other studies showed a similar distribution. 12, 19, 26 Future studies with a large-enough number of patients to cover all the ChildePugh classifications could define a clearer relationship between the liver enhancement and the ChildePugh classification. Second, the delay time of the two contrast agents was different. The delay time for GdeDTPA is 180 seconds, and the delay time for GdeEOBeDTPA is 20 minutes. This may be due to the different excretion routes of the two contrast agents. Previous studies also suggested using the different delay times for daily practice. 9, 27 Therefore, using different delay times to compare the two contrast agents is acceptable.
In conclusion, the enhancement effect of the liver with GdeEOBeDTPA was higher than with GdeDTPA in the VP and DP. Conversely, the enhancement effect of the kidney with GdeDTPA was significantly higher than with GdeEOBeDTPA in the DP. The enhancement effect of the liver was not affected by liver cirrhosis or abnormal liver function. However, the enhancement of the liver in the HP of GdeEOBeDTPA-enhanced MRI could be affected by the serum-bilirubin levels. GdeEOBeDTPA is helpful when performing dynamic MRIs and in the HP for diagnosing focal hepatic lesions in the heterogeneous liver parenchyma.
